Literature DB >> 20103057

Prognostic factors of vitreous hemorrhage secondary to exudative age-related macular degeneration.

Tomoko Hasegawa1, Atsushi Otani, Manabu Sasahara, Norimoto Gotoh, Sotaro Ooto, Hiroshi Tamura, Kenji Yamashiro, Akitaka Tsujikawa, Nagahisa Yoshimura.   

Abstract

PURPOSE: Vitreous hemorrhage (VH) is a rare but serious complication of the eyes with exudative age-related macular degeneration (AMD). This retrospective study was designed to evaluate various clinical factors that may affect the visual prognosis of patients with VH secondary to exudative AMD.
DESIGN: Retrospective case study.
METHODS: We intensively documented 31 cases of VH secondary to exudative AMD and retrospectively analyzed best-corrected visual acuity (BCVA). All eyes underwent standard pars plana vitrectomy (PPV) for treating VH. Three subgroups were created according to the clinical course and treatment history before the occurrence of VH: (1) gas group (7 eyes), pneumatic displacement with sulfur hexafluoride gas performed to treat massive submacular hemorrhage; (2) photodynamic therapy (PDT) group (9 eyes), PDT performed to treat exudative AMD; (3) untreated group (15 eyes), no treatment performed.
RESULTS: As a whole, BCVA before the occurrence of VH was 1.05 +/- 0.59 (logarithm of the minimal angle of resolution). After the occurrence of VH, BCVA before PPV dropped to 2.61 +/- 0.82. After the operation, final BCVA improved significantly to 1.25 +/- 0.73 (P< 10(-8)). In a subgroup analysis, no statistically significant difference was seen among the 3 subgroups at any time point. We found that the eyes whose fellow eye had exudative AMD showed significantly poor final BCVA compared with the unilateral cases (0.92 +/- 0.57 and 1.49 +/- 0.72; P = .02).
CONCLUSIONS: PPV can improve visual acuity in the eyes with VH secondary to AMD, although effectiveness is limited. Medical practitioners should be cautious of the visual prognosis, especially in the cases in which the fellow eye has exudative AMD. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20103057     DOI: 10.1016/j.ajo.2009.09.012

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration.

Authors:  H S Kim; H J Cho; S G Yoo; J H Kim; J I Han; T G Lee; J W Kim
Journal:  Eye (Lond)       Date:  2015-08-14       Impact factor: 3.775

2.  Surgical outcomes of vitrectomy for breakthrough vitreous hemorrhage in eyes with exudative age-related macular degeneration.

Authors:  Takehito Iwase; Takayuki Baba; Yuya Saito; Tomohiro Nizawa; Hirotaka Yokouchi; Mariko Kubota-Taniai; Masayasu Kitahashi; Shuichi Yamamoto
Journal:  Int Ophthalmol       Date:  2021-02-21       Impact factor: 2.031

3.  Surgical management of submacular hemorrhage due to n-AMD: a comparison of three surgical methods.

Authors:  Carsten Grohmann; Spyridon Dimopoulos; Karl Ulrich Bartz-Schmidt; Philipp Schindler; Toam Katz; Martin S Spitzer; Christos Skevas
Journal:  Int J Retina Vitreous       Date:  2020-07-02

4.  Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration.

Authors:  Setsuko Kawakami; Yoshihiro Wakabayashi; Kazuhiko Umazume; Yoshihiko Usui; Daisuke Muramatsu; Tsuyoshi Agawa; Kaori Yamamoto; Hiroshi Goto
Journal:  J Ophthalmol       Date:  2021-11-02       Impact factor: 1.909

5.  Prognostic Factors and Long-term Surgical Outcomes for Exudative Age-related Macular Degeneration with Breakthrough Vitreous Hemorrhage.

Authors:  Tae Young Kim; Hyun Goo Kang; Eun Young Choi; Hyoung Jun Koh; Sung Soo Kim; Ji Hwan Lee; Min Kim; Suk Ho Byeon; Christopher Seungkyu Lee
Journal:  Korean J Ophthalmol       Date:  2020-08

6.  Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage.

Authors:  Yong-Il Shin; Jae-Yun Sung; Min Sagong; Young-Hoon Lee; Young-Joon Jo; Jung-Yeul Kim
Journal:  Sci Rep       Date:  2018-07-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.